Will Howe

Will Howe

Auto-generated profile, based on publicly available information

Will Howe

Information Management Services, Inc. , Calverton, MD 20705

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
Philip LupoPhilip Lupo
Philip Lupo
DSDavid A Siegel
David A Siegel
NSNicola C Schussler
Nicola C Schussler
TATodd A Alonzo
Todd A Alonzo
SASuzanne Adams
Suzanne Adams
LPLynne Penberthy
Lynne Penberthy
Background: Improvements in outcomes among children and adolescents diagnosed with cancer are attributable to many factors, including clinical trials such as those administered through the Children’s Oncology Group (COG) as well as population-based resources such as the National Childhood Cancer Registry (NCCR). The objective of this study was to link COG trial data with the NCCR to evaluate overall enrollment patterns. Methods: Data were received from the NCCR and COG that were linked using an array of variables, then compared to evaluate enrollment patterns in COG studies from 2007 to 2018. Multivariable logistic regression was used to identify characteristics associated with not being enrolled in a COG study. Results: Among 134 696 NCCR patients with cancer, 51 062 matched with COG study enrollees. There were several differences in demographic and clinical characteristics between individuals enrolled and not enrolled in COG studies. Enrollment was higher among children aged from birth to 4 years compared with adolescents aged 15-19 years (53.7% vs 20.1%). Differences by race and ethnicity were also observed; for example, individuals who identified as non-Hispanic White were more likely to be enrolled than were individuals who identified as non-Hispanic Asian or Pacific Islander (38.8% vs 32.9%). In a multivariable logistic regression model, several characteristics were strongly associated with not being enrolled in a COG study, including age at diagnosis, year of diagnosis, race and ethnicity, and cancer type. Conclusion: Our results suggest that several groups are underrepresented in COG clinical trials. This information can help guide the prioritization of population groups for engagement in future studies.

27 October 2025 in Journal of the American Medical Informatics Association
Verified
Journal Article
Closed access
MKMurat Kantarcioglu
Murat Kantarcioglu
WHWill Howe
Will Howe
BLBenmei Liu
Benmei Liu
VPValentina Petkov
Valentina Petkov
ECEsmeralda Casas-Silva
Esmeralda Casas-Silva
LPLynne Penberthy
Lynne Penberthy
Objective: The National Cancer Institute (NCI), part of the National Institutes of Health (NIH) supports efforts to address critical challenges in advancing cancer research. As part of this effort, NCI sponsored the development of a privacy-preserving record linkage (PPRL) software that transforms identifying patient information into multiple tokens through a set of cryptographically secure keyed hash functions. This project aims to evaluate the PPRL software in the perspective of re-identification risks and propose effective strategies to sufficiently mitigate these risks. Materials and Methods: To achieve the goals, we developed a novel re-identification risk assessment framework, based on token frequency analysis, to estimate the privacy impact of hashed tokens shared for record linkage. We assessed privacy risk through empirical analysis on a state-level voter registration database, a public dataset commonly used for re-identification, under various scenarios. These scenarios are defined based on several factors, including the size of the dataset used for linkage and a group size parameter that determines when an adversary can claim that a record has been re-identified. Results: We found that the re-identification risk based on frequency analysis attack is approximately 0.0002 (ie, 2 patients out of 10 000 are potentially identifiable) under reasonable adversarial settings, with a group size parameter of k = 12 and a dataset size of 400 000 patients. Additionally, our analysis reveals a negative correlation between dataset size and re-identification risk. Discussion: Re-identification risk is deemed low for the new NCI PPRL software. Token frequency analysis provides a reliable estimate of the re-identification risk in token-based PPRL tools.